• ImmunityBio reported preliminary results from a health economic analysis that were presented at ISPOR 2026 on May 17-20.
• The analysis found ANKTIVA with BCG delivered better economic value than TAR-200 in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ, driven by a higher rate of durable responses and fewer bladder removals.
• Across a three-year Medicare-based model, ANKTIVA with BCG showed lower costs per sustained responder, lower costs tied to avoiding cystectomy, and lower costs per cystectomy-free time than TAR-200.
• The cost advantage was attributed mainly to lower treatment acquisition and administration costs in the model.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunitybio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605220730BIZWIRE_USPR_____20260522_BW861965) on May 22, 2026, and is solely responsible for the information contained therein.